First-month promotional rates published as ongoing prices
A recurring error across round-ups, and the likely origin of several wrong figures.
A recurring error across round-ups, and the likely origin of several wrong figures.
All-in monthly cost at 10 mg
Many programmes advertise a discounted first month that reverts to a materially higher ongoing rate, and round-ups repeatedly publish the promotional figure as the standing price.
The effect compounds with dose-scaling: a promotional entry price at a programme that also reprices with dose can understate a twelve-month total by more than a thousand dollars.
Ask whether the quoted rate holds at renewal, and get it in writing.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
The cheapest verified compounded route we track currently sits at $215 a month all-in at a 10 mg maintenance dose, about $2,580 for a first year. Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.